さまよう薬剤師のブログ

学位を持っても、センスのない、感染制御専門薬剤師のブログ.  I have Ph.D. but less sense ID pharmacist.

Lancet

Oseltamivir, amantadine, and ribavirin combination antiviral therapy versus oseltamivir monotherapy for the treatment of influenza: a multicentre, double-blind, randomised phase 2 trial

LIDに発表されたインフルエンザ治療のPⅡ。 combination of oseltamivir, amantadine, and ribavirin VS oseltamivir http://www.thelancet.com/journals/laninf/article/PIIS1473-3099(17)30476-0/fulltext

Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial

LIDに報告された、Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1)。単一アーム、オープンラベル、多施設第3相試験。 http://www.thelancet.com/jo…

Hospital antimicrobial stewardship: the way forward

LIDで発表された Effect of antibiotic stewardship on the incidence of infection and colonisation with antibiotic-resistant bacteria and Clostridium difficile infection: a systematic review and meta-analysis http://www.thelancet.com/journals…

Enteral versus parenteral early nutrition in ventilated adults with shock: a randomised, controlled, multicentre, open-label, parallel-group study (NUTRIREA-2)

Lancetに発表された、ショックを伴う人口呼吸器管理の成人における早期の静脈栄養 vs 経腸栄養:ランダム化、制御、多施設、オープンラベル(NUTRIREA-2). http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)32146-3/fulltext

Optimisation of empirical antimicrobial therapy in patients with haematological malignancies and febrile neutropenia (How Long study): an open-label, randomised, controlled phase 4 trial

The Lancet Haematology に発表された、FNのRCT。 empirical antimicrobial therapy はEATと略していました。

Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial

担当は薬学実習生。2nd Generation DacomitinibについてのPIII試験です。 www.ncbi.nlm.nih.gov

Prolonged versus short-term intravenous infusion of antipseudomonal β-lactams for patients with sepsis: a systematic review and meta-analysis of randomised trials

LIDに発表された、抗緑膿菌ベータラクタム系薬の持続投与に関するメタアナ。 http://www.thelancet.com/journals/laninf/article/PIIS1473-3099(17)30615-1/fulltext

Empiric Therapy With Carbapenem-Sparing Regimens for Bloodstream Infections due to Extended-Spectrum β-Lactamase–Producing Enterobacteriaceae: Results From the INCREMENT Cohort

CIDに報告された、ESBL産生菌に対するエンピリック療法に関する内容。 元データは、INCREMENTコホート研究 (Lancet Infect Dis. 2017 Jul;17(7):726-734. )。

Procalcitonin and antibiotic use: imperfect, yet effective

LIDに報告された、プロカルチンと抗菌薬についてのコメント http://www.thelancet.com/journals/laninf/article/PIIS1473-3099(17)30593-5/fulltext

Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial.

9月からJournal Club再開です。 プレゼンターは、呼吸器内科医です。 2016年 Lancet Oncolに発表された、BRAFV600E変異陽性のstageⅣNSCLC患者に対する、dabrafenibとtrametinibの2剤併用のphase 2.

A fatal outbreak of ST11 carbapenem-resistant hypervirulent Klebsiella pneumoniae in a Chinese hospital: a molecular epidemiological study

LIDに報告された、中国の病院におけるST11CR-Kp http://www.thelancet.com/journals/laninf/article/PIIS1473-3099%2817%2930489-9/fulltext

Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial.

今週のJournal Clubプレゼンターは、呼吸器内科医です。 2017年5月 Lancet Oncolに発表された、NSCLCにおけるPembrolizumab治療効果。 KEYNOTE-001(Phase 1)の二次解析を行い、放射線治療歴の有無によるPFSとOSを検討してます。

Effect of antibiotic stewardship on the incidence of infection and colonisation with antibiotic-resistant bacteria and Clostridium difficile infection: a systematic review and meta-analysis

Effect of antibiotic stewardship on the incidence of infection and colonisation with antibiotic-resistant bacteria and Clostridium difficile infection: a systematic review and meta-analysis http://www.thelancet.com/journals/laninf/article/…

Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study

Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. www.ncbi.nlm.nih.gov 2017年4月 Lancet Infect Dis に…

Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial.

Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. www.ncbi.nlm.nih.gov 2016年5月 Lancet Inf Dis に報告された、オランダ15施…

ESTABLISH-2 : Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial.

ESTABLISH-2 : Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial. www.ncbi.nlm.nih.gov 2014年 Lancet Inf Disに…

Antibiotic treatment for 6 weeks versus 12 weeks in patients with pyogenic vertebral osteomyelitis: an open-label, non-inferiority, randomised, controlled trial.

Antibiotic treatment for 6 weeks versus 12 weeks in patients with pyogenicvertebral osteomyelitis: an open-label, non-inferiority, randomised, controlledtrial. 2015年 (Epub2014年) Lancetに報告された、フランス71施設における化膿性脊椎炎患者…

Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial.

Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial. www.ncbi.nlm.nih.gov 2015年Lancetに報告された、スイス7施設による成人の市中肺炎に対するプレドニゾ…

Efficacy and safety of oral solithromycin versus oral moxifloxacin for treatment of community-acquired bacterial pneumonia: a global, double-blind, multicentre, randomised, active-controlled, non-inferiority trial (SOLITAIRE-ORAL).

SOLITAIRE-ORAL : Efficacy and safety of oral solithromycin versus oral moxifloxacin for treatment of community-acquired bacterial pneumonia: a global, double-blind, multicentre, randomised, active-controlled, non-inferiority trial. www.ncb…

Efficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridium difficile infection: a phase 2, randomised, double-blind, active-controlled, non-inferiority study

The Lancet Infectious Diseases Published: April 28, 2017 Efficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridium difficile infection: a phase 2, randomised, double-blind, active-controlled, non-inferio…

Journal Club : Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial

プレゼンターは呼吸器内科の先生 Journal Club : Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial www.ncbi.nlm.nih.gov